APA (7th ed.) Citation

G, G., L, A., R, B., GR, C., M, C., J, D., . . . J, O. (2026). Efficacy and safety of ocrelizumab in primary progressive multiple sclerosis, including older patients and those with more advanced disease (ORATORIO-HAND): A multicentre, double-blind, randomised, placebo-controlled, phase 3b study. Lancet (London, England), 407(10544), 2195. https://doi.org/10.1016/S0140-6736(26)00617-3

Chicago Style (17th ed.) Citation

G, Giovannoni, et al. "Efficacy and Safety of Ocrelizumab in Primary Progressive Multiple Sclerosis, Including Older Patients and Those with More Advanced Disease (ORATORIO-HAND): A Multicentre, Double-blind, Randomised, Placebo-controlled, Phase 3b Study." Lancet (London, England) 407, no. 10544 (2026): 2195. https://doi.org/10.1016/S0140-6736(26)00617-3.

MLA (9th ed.) Citation

G, Giovannoni, et al. "Efficacy and Safety of Ocrelizumab in Primary Progressive Multiple Sclerosis, Including Older Patients and Those with More Advanced Disease (ORATORIO-HAND): A Multicentre, Double-blind, Randomised, Placebo-controlled, Phase 3b Study." Lancet (London, England), vol. 407, no. 10544, 2026, p. 2195, https://doi.org/10.1016/S0140-6736(26)00617-3.